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Abstract
Background: Affymetrix oligonucleotide arrays simultaneously measure the abundances of
thousands of mRNAs in biological samples. Comparability of array results is necessary for the
creation of large-scale gene expression databases. The standard strategy for normalizing
oligonucleotide array readouts has practical drawbacks. We describe alternative normalization
procedures for oligonucleotide arrays based on a common pool of known biotin-labeled cRNAs
spiked into each hybridization. 
Results: We first explore the conditions for validity of the ‘constant mean assumption’, the key
assumption underlying current normalization methods. We introduce ‘frequency normalization’, a
‘spike-in’-based normalization method which estimates array sensitivity, reduces background noise
and allows comparison between array designs. This approach does not rely on the constant mean
assumption and so can be effective in conditions where standard procedures fail. We also define
‘scaled frequency’, a hybrid normalization method relying on both spiked transcripts and the
constant mean assumption while maintaining all other advantages of frequency normalization. We
compare these two procedures to a standard global normalization method using experimental
data. We also use simulated data to estimate accuracy and investigate the effects of noise. We find
that scaled frequency is as reproducible and accurate as global normalization while offering several
practical advantages. 
Conclusions: Scaled frequency quantitation is a convenient, reproducible technique that performs as
well as global normalization on serial experiments with the same array design, while offering several
additional features. Specifically, the scaled-frequency method enables the comparison of expression
measurements across different array designs, yields estimates of absolute message abundance in cRNA
and determines the sensitivity of individual arrays.
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Background
Affymetrix  oligonucleotide  arrays  (referred  to  here  as
oligonucleotide arrays) are widely used to measure the abun-
dance  of  mRNA  molecules  in  biological  samples  [1].  The
investigator isolates total and/or polyadenylated RNA from
cells or tissues, generates the corresponding complementary
DNA (cDNA), transcribes complementary RNA (cRNA) from
the  cDNA  template,  and  then  hybridizes  the  cRNA  to  the2 Genome Biology Vol 2 No 12 Hill et al.
array [2]. There is a significant amount of assay noise associ-
ated with readouts from oligonucleotide arrays (for example
[3,4]). For these arrays we have found additive and multi-
plicative noise affecting individual gene readouts (typically
5-20%), as well as multiplicative noise affecting entire arrays
(often above 20%). As defined here, normalization attempts
to  correct  for  only  the  latter  type  of  noise.  The  primary
sources of this array-level noise are between-array variation
in overall performance (due to inconsistencies in array fabri-
cation, staining and scanning), and between-cRNA variation
(as  independently  prepared  cRNAs  have  variable  purity
and/or fluorescently-labeled mass fractions). Because these
sources of variation contribute so significantly to array read-
outs, normalization is a critical first step in any analysis of
gene expression data.
Most current normalization procedures for oligonucleotide
arrays are global approaches, based on normalization of the
overall mean or median array intensity to a common stan-
dard (for example [5-7]). Spiked standards have also been
used  to  normalize  cDNA  [8]  and  oligonucleotide  [9-11]
arrays. All these techniques are inherently linear; there have
been recent reports of nonlinear normalizations for cDNA
[12],  oligonucleotide  [13,14]  and  other  [15]  arrays.  Few
detailed comparisons of oligonucleotide-array normalization
procedures have been reported, however [13].
For oligonucleotide arrays, the normalization implemented
in the Affymetrix GeneChipTM software (Affymetrix, Santa
Clara, CA) is by far the most commonly used (for example
[1,16]). In this approach, the mean hybridization intensities
(the  ‘average  differences’  (AD))  of  all  probe  sets  on  each
array are scaled to an arbitrary, fixed level [17]. In the rest of
this paper, we refer to this procedure as ‘global normaliza-
tion’ or scaled average difference (ADs). In practice, there are
at least three limitations to this method. Of these, the first
two relate to the normalization itself, and the last relates to
the practical utility of the normalized readouts.
First, global normalization makes no attempt to absolutely
quantify mRNA abundances. Readouts are normalized to an
arbitrary scale, which may vary from one operator to another
or between experiments. In contrast, previous experiments
with spiked controls [1] and comparisons with serial analysis
of  gene  expression  (SAGE)  [18]  have  shown  that  array
response can be proportional to true transcript abundance,
suggesting that absolute quantitation of transcripts is feasi-
ble.  If  sufficiently  accurate,  such  an  absolute  scale  for  all
array  readouts  could  facilitate  comparisons  across  large,
diverse gene expression databases.
Second,  global  normalization  implicitly  assumes  that  the
mean expression level of all monitored mRNAs is constant.
The validity of this assumption depends on the number and
biological  characteristics  of  genes  monitored  by  an  array.
For smaller arrays that monitor a limited set of mRNAs, this
assumption is invalid and may result in erroneous normal-
ization. Ideally, a quantitation method for arrays would be
effective even in cases where this ‘constant mean’ hypothesis
does not hold.
Third,  as  typically  applied,  global  normalization  does  not
deal well with transcripts expressed at low copy numbers. In
a typical Affymetrix GeneChip assay, many low-abundance
transcripts  are  present  at  levels  below  the  sensitivity  of
detection of the array (typically about 1:100,000 mRNAs).
Measurements for such mRNAs are not only noisy but are
sometimes negative, due to cross-hybridization to mismatch
probes  [1].  Negative  intensity  values  are  meaningless  and
problematic  because  they  cannot  be  log-transformed,  a
manipulation  that  is  a  common  prelude  to  downstream
analysis of array data. Simply discarding negative values is
objectionable as it can lead to missed observations of biolog-
ically significant upregulation. An automated normalization
method that handles noisy and negative measurements and
responds to variable array sensitivity is desirable, especially
in a high-throughput setting.
The primary criterion for any alternative to global normal-
ization is that it should expand the investigator’s ability to
compare diverse array experiments done at different times
in different laboratories. In this paper, we describe alterna-
tive procedures that seek to quantitate array results in terms
of transcripts per unit cRNA. We chose cRNA quantitation
because it meets the primary criterion, and for several addi-
tional reasons.
First, cRNA quantitation is easily applied to array experi-
ments using small amounts of starting total RNA that are
difficult  to  quantitate  accurately.  Second,  the  spike
reagents described here for cRNA quantitation can be used
to  specifically  monitor  the  performance  of  individual
arrays. Third, in our experience, the reproducibility, accu-
racy and scientific value of cRNA quantitation are at least
as good as those of alternative techniques, such as proce-
dures  to  quantitate  transcripts  per  cell,  transcripts  per
mass of input material, transcripts per total RNA or tran-
scripts per polyadenylated RNA.
We evaluated two alternatives to the standard global nor-
malization scheme which we term ‘frequency’ (F) and ‘scaled
frequency’  (Fs)  normalization.  These  normalization  proce-
dures are based on the presence of a common pool of biotin-
labeled transcripts of known concentrations spiked into each
hybridization. Constructs for generating the control reagents
are available through the American Type Culture Collection
(ATCC); accession numbers are given in Table 1. We describe
how scaled frequency normalization can be used to estimate
message  abundance  in  cRNA,  compute  a  chip  sensitivity
metric  and  provide  a  natural  scale  for  damping  spurious
signals  from  below-sensitivity  mRNAs.  Using  previously
published  replicated  experimental  hybridizations  and  newc
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simulated data, we compare the reproducibility and accuracy
of  frequency,  scaled  frequency  and  global  normalization.
Our results suggest that scaled frequency normalization is a
useful strategy for oligonucleotide array data and has impor-
tant advantages over current approaches.
Results and discussion
The constant-mean assumption
A  key  assumption  underlying  global  normalization  is  that
the mean expression level on an array should be the same for
all samples and all arrays. This assumption is distinct from
the  additional  implicit  assumption  that  the  fraction  of
polyadenylated mRNA per total RNA is constant. One can
certainly  construct  special  cases  where  the  constant-mean
assumption is invalid. One example would be using a small
array  containing  only  genes  from  a  single  pathway  in  an
experiment that studies variable induction of that pathway.
However,  it  is  unclear  how  well  even  more  general  array
experiments satisfy this assumption. 
To  evaluate  the  constant-mean  assumption  we  examined
the coefficient of variation (CV) of the mean expression level
of  variable-sized  mRNA  sets  across  samples  covering
widely divergent  developmental  stages  of  the  nematode
Caenorhabditis elegans. We constructed the largest possible
subset of our data that included only matched triplets of the
A, B and C array designs (see Materials and methods). The
subset comprised 39 chip hybridzations, 13 of each design,
covering all developmental stages. This dataset represents a
relatively  strong  test  of  the  constant  mean  assumption,
because very large biological modulation of many mRNAs
occurs across the dataset. As the C. elegans arrays monitor
around 98% of all predicted C. elegans mRNAs, and the sum
of the relative expression levels of all expressed genes must
be constant by definition, global normalization is well justi-
fied for the dataset as a whole. Thus, the 13 experimental
hybridizations  of  each  array  design  were  globally  normal-
ized, and subsets of the 19,031 total mRNAs monitored by
the arrays were selected at random. For each subset, the CV
of  the  mean  expression  level  of  the  subset  across  all  13
hybridizations was computed. Subsets ranged in size from 10
to  19,031  genes  (0.05%  to  100%  of  this  transcriptome)
(Figure 1). The CV of the mean expression level is below 7%
for any set of mRNAs larger than roughly 10% of the total. As
this CV is no larger than the typical contribution of other
noise sources in the readout, we conclude that the constant-
mean assumption can be supported for arrays that monitor
on the order of 20-100% of a transcriptome. This is typical of
current commercial arrays for several bacteria, yeast, mouse
and human. 
Table 1
Spike-in transcript pool
Spiked ATCC Affymetrix  Final  Final 
transcript accession gene  concentration  concentration 
number qualifier (pmol) (ppm)
DAPM 87826 AFFX-DapX-M_at 30 950
DAP5 87827 AFFX-DapX-5_at 10 317
CRE5 87832 AFFX-CreX-5_at 5 158
BIOB5 87825 AFFX-BioB-5_at 2.5 79
BIOD3 87830 AFFX-BioDn-3_at 1.2 38
BIOB3 87828 AFFX-BioB-3_at 0.6 19
CRE3 87835 AFFX-CreX-3_at 0.4 13
BIOC5 87833 AFFX-BioC-5_at 0.3 10
BIOC3 87834 AFFX-BioC-3_at 0.2 6
DAP3 87831 AFFX-DapX-3_at 0.15 5
BIOBM 87829 AFFX-BioB-M_at 0.1 3
Spike-in transcript pool. The 11 spiked transcripts and their final
concentrations in the hybridization cocktails are listed. The Affymetrix
gene qualifier column indicates the name of the probe set on Affymetrix
arrays that monitors each spiked transcript.
Figure 1
When to use constant-mean normalization. The constant-
mean assumption adds little noise for array designs with
sufficiently large numbers of randomly selected genes.
Assuming that the mean expression on arrays in a dataset
would indeed be constant for an array monitoring the entire
transcriptome, we chose random subsets of genes of each
possible size and computed the CV of the mean expression
level for hypothetical arrays monitoring just those subsets of
genes. For arrays measuring more than about 10% of the
genes, the level of variability introduced is not significantly
larger than other sources of array variability, so
normalization using the constant-mean assumption is
reasonable. With fewer genes, the noise introduced by
making this assumption grows dramatically, so other
normalization methods may be desirable. Note that if there
is bias in the selection of genes on the array, this effect may
be much stronger. 
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are randomly selected with respect to their expression char-
acteristics. The example noted above (all genes on an array
from  a  single  pathway)  is  an  extreme  case  of  nonrandom
selection. Other common ways of selecting genes for arrays
may also violate this assumption, including selection based
on matches in specific cDNA libraries. 
Nonrandom selection of even large mRNA sets for individual
arrays  can  also  lead  to  between-array  inconsistencies  in
mean expression level. For example, consider the case of two
arrays, each monitoring a large, equal percentage (> 20%) of
a transcriptome, where the first array monitors mRNAs with
confirmed cDNA library matches, and the other array moni-
tors  mRNAs  whose  sequences  are  based  on  lower-quality
expressed sequence tag (EST) sequence matches or compu-
tational gene predictions. While the constant mean assump-
tion  is  justified  for  each  array  in  isolation,  comparison  of
globally normalized expression levels between the two arrays
will  give  erroneous  results  because  the  mean  expression
level of transcripts on the first array is higher than that on
the second.
Spike-in based normalization
The limitations of global normalization suggest the use of
spiked  transcripts  to  normalize  array  data.  Our  ‘spike-in’
normalization method, which we call ‘frequency normaliza-
tion’, uses spiked transcripts for two purposes. First, they
allow us to calibrate the arrays, transforming AD to cRNA
frequency  (F)  estimates  quoted  in  transcripts  per  million.
Second,  the  spiked  transcripts  enable  us  to  estimate  the
minimum detectable frequency on the array (the ‘array sen-
sitivity’ value). The array sensitivity is useful as a quality-
control metric for individual hybridizations and is also used
to adjust signals from low-level transcripts. Specifically, fre-
quency values below the array sensitivity are averaged with
the  sensitivity  estimate  to  generate  ‘damped’  frequencies
that lie between 50% and 100% of the array sensitivity. This
adjustment  introduces  a  small  systematic  error  into  the
damped data, but in return it eliminates problematic nega-
tive values and retains low-level readings that can be biologi-
cally informative in the context of additional experiments.
Figure 2 shows a typical plot of the spiked transcript readout
from a single hybridization containing 2 g of cRNA and a
corresponding amount of spike-in transcripts. The specific
hybridization intensity (AD) value for each of the 11 spike-in
controls is plotted as a function of transcript frequency in
units of transcripts per million. The points are fitted with a
generalized linear model that is then used as a calibration
curve  to  compute  frequencies  from  the  AD  values  of  the
other genes on the array. Using logistic regression, we define
the  chip  sensitivity  as  the  frequency  where  we  estimate  a
gene to have a 70% probability of being called ‘Present’. We
will use the capitalized terms ‘Absolute Decision’, ‘Present’,
‘Absent’  and  ‘Marginal’  when  referring  to  a  specific  value
that  is  calculated  by  the  Affymetrix  GeneChip  software
(described in Materials and methods). In Figure 2, the verti-
cal line at a frequency of 4.5 indicates the computed sensitiv-
ity estimate for this array.
Fitting a power law model (AD = kFn) to the data in Figure 2
yields the exponent n = 0.93. This indicates mild curvature
in  the  response,  consistent  with  progressive  saturation  of
array  readout  for  the  highest  abundance  mRNAs.  Experi-
ments using 0.1 to 10 g cRNA per hybridization with corre-
sponding  amounts  of  spike-in  transcripts,  as  well  as  high
and low gain settings on the scanner, indicated that readout
saturation (not hybridization saturation) accounted for most
of the observed curvature in the spike-in response. The use
of  approximately  1 g  cRNA  in  each  hybridization,  or
reduced scanner gain, largely eliminated saturation with no
penalty in sensitivity.
Scaled frequency normalization
Frequency normalization is appealing theoretically and effec-
tive even when the constant-mean assumption is known to be
invalid.  However,  our  experience  suggests  that  frequency
estimates might be biased by experimental limitations on the
4 Genome Biology Vol 2 No 12 Hill et al.
Figure 2
The calibration model for frequency normalization. Eleven
control transcripts are spiked into the hybridization solution
at known concentrations, and the absolute difference (AD)
measurements for these controls are plotted against their
known frequencies. P and A represent Present and Absent
calls, respectively, from Affymetrix GeneChip software.
Hybridization response in average difference (AD) is
approximately proportional to transcript abundance. The
solid fitted line is a linear model with intercept zero, which
is used to calculate frequencies for all other transcripts on
the array. The vertical line at 4.5 ppm represents the
calculated limit of detection for this particular array;
frequencies below that level are damped to avoid attributing
significance to expression differences caused by assay noise. 
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cRNA.  Specifically,  because  of  the  combination  of  small
fluid-handling uncertainties and potentially larger variation
in the purity of cRNA preparations, the actual ratio of the
spiked transcripts to cDNA-template-derived cRNAs might
be  significantly  skewed  from  one  array  to  another.  One
source of variable impurities in cRNA preparations could be
oligo(dT)-primer-dependent cRNA product [19]. Such cRNA
impurities would result in erroneous normalization in which
all readouts from one array would be systematically higher
or lower than those from another array. We use the term
‘spike-skew’ to denote this multiplicative skew in frequency
values  among  multiple  hybridizations.  One  expected
symptom  of  spike-skew  would  be  replicate  hybridization
readouts that are highly correlated but have widely divergent
mean expression levels.
We developed the hybrid scaled frequency (Fs) normaliza-
tion method to mitigate the effects of spike-skew. Fs normal-
ization  is  based  on  the  principle  of  removing  technical
variation in the ratio of spiked transcripts to cDNA-template-
derived cRNAs, by averaging the response to spiked cRNAs
over multiple hybridizations. To compute Fs values, globally
scaled average differences are first computed for all arrays in
a set. This initial step implicitly makes the constant-mean
assumption.  A  calibration  function  is  then  computed  by
fitting a single linear model to the scaled average differences
of all spiked cRNAs on all the arrays in the dataset, pooled
together. Individual array sensitivities are still computed as
described above, and the same damping of low-end frequen-
cies is carried out using the sensitivity values for each array. 
To compare F and Fs metrics, consider an experimental set
of ten arrays. To compute F values, ten linear models are
fitted  to  the  ten  distinct,  unscaled  AD  responses  to  the
spiked cRNAs, yielding ten different calibration factors, one
for  each  array.  In  contrast,  when  computing  Fs values,  a
single  linear  model  is  fitted  to  the  pooled  spike  response
curve consisting of 10 x 11 = 121 globally scaled AD values,
and a single calibration factor generated for all ten arrays. If
there was no technical variation in the ratio of spiked tran-
scripts to cDNA-template-derived cRNAs in the ten experi-
ments, both approaches would give the same quantitation,
up  to  a  random  error  term  arising  from  the  difference
between  fitting  ten  11-point  responses  versus  a  single
121-point response. If, in one of the ten arrays, the ratio of
spiked transcripts to cDNA-template-derived cRNAs is dif-
ferent  for  technical  reasons,  then  spike  response  for  that
array will be skewed, and the F-metric readout for that array
will be skewed relative to the other nine arrays. In contrast,
such  a  skewed  array  will  only  affect  the  Fs metric  to  the
extent that the single skewed response shifts the fit to the
pooled spike response. The skew for the single problematic
array will be removed because all arrays in the set will be
scaled and calibrated with a single factor. In other words, Fs
values are estimates of transcript abundance in cRNA, based
on the average response to the spiked cRNAs over multiple
hybridizations and on the sensitivity of each individual array.
F values provide the same estimate, but based solely on the
response to spiked cRNAs in a single array hybridization.
Comparison of normalization methods: reproducibility
We compared the performance of four metrics: AD; globally
normalized AD (ADs); frequency (F); and scaled frequency
(Fs). The basis for comparison was experimental data con-
sisting of four sets of replicated hybridizations (each n =3   o r
4) of the same array design (the C. elegans A array). Perfor-
mance of each metric was measured by the median absolute
coefficient of variation (MEDACV) of probe sets across the
replicated hybridizations. MEDACV is a measure of repro-
ducibility for which a value of zero indicates perfect agree-
ment  of  all  transcript  readouts  in  a  set  of  replicated
hybridizations.  We  compared  MEDACV  for  two  classes  of
mRNAs:  those  called  Present  in  at  least  50%  of  replicated
hybridizations (referred to as ‘Present’ mRNAs), and those
Present in fewer than 50% of the replicated hybridizations
(referred to as ‘Absent’ mRNAs). All metrics showed higher
(worse)  MEDACVs  for  the  low-abundance  Absent  mRNAs
than for the higher-abundance Present mRNAs (Figure 3), as
expected  from  the  presence  of  background  noise  on  the
arrays. For Present genes, ADs was more reproducible than
AD, as expected. Scaled frequency (Fs) was as reproducible as
ADs for Present genes in all replicate sets, and yielded trivially
higher reproducibility than ADs for Absent mRNAs, owing to
damping of background noise. Frequency appeared equiva-
lent to Fs and ADs in the first set of experiments (the 0-hour
timepoint) but had a higher MEDACV than Fs in the other
three replicate sets. We also computed Pearson correlation
coefficients for the same replicate readouts. Unlike MEDACV,
correlation  coefficients  between  replicate  readouts  were
similar for all metrics (in the range from 0.978-0.996).
To better understand the reasons for the markedly different
MEDACV performances of the four metrics on experimental
replicates,  we  performed  simulations.  These  simulations
incorporated several adjustable noise parameters. We esti-
mated  values  for  these  parameters  iteratively,  based  on
experimental data (see Materials and methods). The similar-
ity  in  the  CV  distributions  of  experimental  and  simulated
data indicated that, for our purposes, the simulations reca-
pitulated  the  major  error  properties  of  real  array  data
(Figure 4).
We tested if spike-skew could account for the relatively high
CV of frequency in three of the four replicate sets (Figure 3) by
comparing experimental data to simulated data with known
levels of spike-skew. To approximate spike-skew, the concen-
tration of the spike-in transcripts in simulations was multi-
plied by a random noise term. Over a series of simulations, we
varied the standard deviation of the noise term from 0 to 40%
to model the effect of increasing spike-skew. MEDACV values
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http://genomebiology.com/2001/2/12/research/0055.5were then computed from the simulation results in the same
way as for the experimental data in Figure 3. 
As  expected,  only  frequency  was  sensitive  to  spike-skew
(Figure 5). The Fs metric, which uses a single standard curve
pooled  from  each  dataset  to  normalize  all  arrays  in  that
dataset, effectively eliminated spike-skew effects. In the sim-
ulations, a spike-skew level of 20% led to MEDACV values
for frequency in simulated replicates that were much higher
than those of ADs or Fs. These results were highly reminis-
cent of the 36, 48 and 60 hour experimental replicate sets
(compare Figures 5 and 3).
Taken together, the experimental data and the simulations
suggest  that  spike-skews  of  roughly  20%  can  explain  the
sometimes  inferior  MEDACV  (but  consistently  high  inter-
replicate correlation coefficients) of the frequency metric.
Comparisons across array designs
We  next  considered  the  reproducibility  of  readouts  of  the
same mRNA on different array designs. For this analysis, we
selected the three mRNAs that were monitored by identical
probe sets on each of the A, B, and C array designs and were
called  Present  in  all  hybridizations  of  the  0  hour  cRNA
sample. The observed CV of the ADs metric was in all cases
6 Genome Biology Vol 2 No 12 Hill et al.
Figure 3
Reproducibility of four normalization methods. For each of four developmental stages in a C. elegans data set (0, 36, 48 and
60 h, see [10]), the figure shows the median absolute coefficient of variation (MEDACV) for each normalization method, for
genes that are primarily Absent or primarily Present in replicate hybridizations. For Absent genes, frequency methods have
lower MEDACV than AD methods because of the damping of low-end noise. For Present genes, Fs and ADs are roughly
equivalent and outperform the unscaled methods in all cases. Numbers of replicate hybridizations were three (36 h sample)
or four (0, 48, 60 h samples).
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Vlarger than that of the F or Fs metric, and was greater than
0.55 for all three mRNAs, indicating very poor agreement of
readouts from different array designs when global normal-
ization was used (Figure 6). In contrast, the CVs of both F
and Fs metrics were lower, with CVs for Fs in particular aver-
aging  0.19  (range  0.13-0.29).  The  mRNA  K11C4.5  was
expressed at > 10-fold lower levels than either of the other
two mRNAs, and thus had higher CV values for both F and
Fs than the other two mRNAs. Comparison of the across-
array-design  CVs  to  the  within-array-design  CVs  for  the
three transcripts in Figure 6 indicates that the reproducibil-
ity of ADs was substantially poorer when comparing across
array  designs  rather  than within arrays.  Specifically,  ADs
across-array CV was 3.2- to 6.4-fold higher than the within-
array CV. In contrast, the across-array CV for Fs was only
1.3- to 1.6-fold higher than the corresponding within-array
CV (Table 2).
The reason for the poor agreement of ADs readouts across
distinct designs was that the mRNAs monitored by the A
array are, on average, expressed at higher levels than those
on the B or C array, as confirmed by two independent lines
of evidence. First, the mRNAs on the A array were inten-
tionally  selected  because  they  were  represented  in
C. elegans cDNA  libraries,  whereas  the  B  and  C  array
genes  (many  of  them  computational  predictions)  were
generally  not  represented  in  cDNA  libraries.  Second,  A
array mRNAs were more likely than B or C array mRNAs
to be detected in the developmental time course by the
Affymetrix Absolute Decision metric [10]. Because of this
systematic difference between gene sets, the mean AD of
all A array genes was substantially higher than that of the
genes on the B or C arrays. The ADs metric scales data
under the assumption that mean expression levels for all
arrays should be equal. Therefore, ADs values for genes on
the B and C arrays were inappropriately inflated relative
to ADs values from the A array. 
Comparison of normalization methods: accuracy
Normalization methods should accurately measure true bio-
logical variation. We tested the accuracy of the four methods
using simulated data. As a baseline we chose the experimen-
tal data from one of the 0-hour replicates on the A array. We
generated 19 simulated experimental conditions to produce
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
http://genomebiology.com/2001/2/12/research/0055.7
Figure 4
Noise distributions (CV) for the experimental and simulated data sets. (a) 0-hour dataset; (b) simulated dataset. Simulation
noise parameters were iteratively estimated from the real data (see Materials and methods). The resulting distributions were
sufficiently similar to allow the use of simulations to explore the effects of different sorts of noise on normalization methods.
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(a) (b)20 raw average difference values for each of 6,617 genes. For
each of the four metrics, computed fold-changes between the
modulated  condition  and  the  baseline  (considering  only
messages  called  Present)  were  compared  to  the  true  fold-
changes. Accuracy was defined as the fraction of computed
fold-changes that were accurate within twofold, and deter-
mined for assumed levels of spike-skew from 10-40% (per-
centage is the ratio of standard deviation (SD) to mean of the
random spike-skew term in the simulation). Three simula-
tions were carried out at each level of assumed spike-skew.
ADs and Fs metrics performed equally well and best overall,
with  accuracies  above  99%  regardless  of  spike-skew.  As
expected, frequency was the only metric with a significant
dependence on the level of spike-skew. At 10% spike-skew,
frequency  accuracy  was  (mean  SD)  0.9951  0.0006,  at
20%, 0.96  0.02, and at 40%, 0.82  0.06. For comparison,
the accuracy of AD was 0.88  0.07 at 10% spike-skew, and
did not change significantly at higher spike-skew levels. 
We stress that the overall accuracy levels reported here are
highly dependent on adjustable parameters in our simula-
tion model (see Materials and methods). Nevertheless, the
simulations demonstrate that at levels of spike-skew consis-
tent with our experience, scaled frequency is as accurate as
globally  normalized  ADs;  this  observation  is  robust  to
changes in the model parameters.
8 Genome Biology Vol 2 No 12 Hill et al.
Figure 5
Reproducibility of normalization methods for different degrees of spike-skew in simulated data. The SD of the random
multiplicative spike-skew term in the simulations was adjusted from 0.1 to 0.4 (10-40%). Increasing spike-skew specifically
degrades the performance of the F metric. Note that the relatively poor performance of F relative to Fs and ADs when the
spike-skew is 0.2 (20%) is similar to that observed in the experimental data (Figure 3). Twenty simulated hybridizations were
generated for each level of spike-skew. 
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VAbsolute quantitation of cRNA and cellular RNA
There  are  several  potential  sources  of  inaccuracy  in  the
cRNA quantitiation given by the scaled frequency metric. 
Our results suggest that there is significant uncertainty in
the  molar  ratio  of  spike-in  mRNAs  to  template-derived
cRNAs  in  any  hybridization  (the  spike-skew  effect).  The
MEDACV for the F metric in Figure 3 is likely one measure
of  this  uncertainty,  as  it  probably  arises  primarily  from
cRNA  purity  variation.  This  uncertainty  leads  to  propor-
tional  differences  between  frequency  metric  readouts  and
true  cRNA  transcript  abundances.  However,  in  the  scaled
frequency method, the simultaneous normalization of larger
datasets  reduces  these  differences  through  averaging.  We
anticipate  that  inaccuracies  of  cRNA  quantitation  arising
from this effect will be reduced by improved methods for
quantitation of cRNA preparations.
For F and Fs, heterogeneity in probe response will lead to
gene-specific biases in quantitation. Our data contains two
observations that allow us to estimate the degree of hetero-
geneity among spiked probe sets. Cursory examination of the
calibration curve (Figure 2) suggests relative responses of the
11 distinct probe sets shown do not vary more than two-fold:
no observations fall more than about a factor of two from the
fitted line. A more rigorous evaluation of probe set hetero-
geneity can be done by comparing the ratio of AD values from
two distinct probe sets that monitor the same transcript in a
single  hybridization.  This  ratio  estimates  the  difference  in
readout that would be observed for a single transcript if a dif-
ferent probe set were selected. This comparison was made for
the 11 spiked transcripts (each array contained two probe sets
for each of these mRNAs). On the basis of 138 ratio measure-
ments from the C. elegans arrays, the 10th-90th percentile
range for the ratio was 0.39-1.44 [10], indicating that for the
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Figure 6
Reproducibility of comparisons across array designs. The CV of repeated measurements of three genes across three array
designs is shown for the four metrics. Frequency (F) and scaled frequency (Fs) were more reproducible than either average
difference (AD) or scaled average difference (ADs).
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sset of control transcripts, the uncertainty in cRNA quantita-
tion due to heterogeneity in probe set responses for 80% of
transcripts was less than threefold.
In addition to these factors leading to inaccuracies in cRNA
quantitation, there are at least two important factors leading
to differences between cRNA abundances and cellular RNA
abundances in the starting biological material. 
First, because cRNA is generated from the polyadenylated
fraction  of  total  cellular  RNA  by  a  linear  amplification
process, frequency estimates will not reflect sample-specific
changes in the fraction of polyadenylated RNA in total cellu-
lar RNA. This may be a desirable feature of frequency esti-
mates,  in  cases  where  per-total-RNA  abundance  is  less
relevant than per-polyadenylated-RNA abundance.
Second, any gene-specific biases in the cRNA amplification
procedure  will  lead  to  gene-specific  differences  between
cRNA  and  per-total-RNA  quantifications.  Evidence  to  date
suggests that these biases are small [1] and reproducible [19].
Taken  together,  the  above-noted  sources  of  inaccuracy
suggest that there can typically be around two- to threefold
differences  between  scaled  frequency  per-cRNA  estimates
and  per-polyadenylated-RNA  abundances  in  the  starting
material. These differences could be reduced by improved
cRNA  process  control  and  quantitation,  and  by  improved
probe selection algorithms. 
Conclusions
We have shown that cRNAs spiked into hybridization solu-
tions at known concentrations covering two to three orders
of magnitude can be used to normalize array data and to
estimate  array  sensitivity.  However,  frequency  normaliza-
tion  based  solely  on  these  control  transcripts  can  be
adversely  affected  by  variations  in  the  ‘purity’  of  cRNA
preparations.  These  observations  underline  the  need  for
meticulous quality control during the production of cRNA
samples and accurate quantitation of the resulting material.
With better control of these processes, the frequency metric
may provide a robust spike-based normalization that, unlike
all  the  other  metrics  described  here,  does  not  rely  on  the
constant-mean assumption.
In the presence of variation in cRNA purity, the Fs metric
provides a compromise between the robustness of the ADs
metric and the more absolute quantitation scale of the fre-
quency metric, in cases where the constant-mean assump-
tion is valid. In addition, the Fs metric provides a common
scale for comparing data from distinct array designs. This is
an important advantage over other metrics. For example, the
Fs metric allows comparison of the expression levels of all
worm mRNAs on all three of our array designs with compa-
rable confidence to within-array-design comparisons. This is
not  possible  with  globally  normalized  average  differences.
We believe that cRNA quantitation and the damping of low-
amplitude  signals  provided  by  the  Fs normalization  make
this  metric  a  valuable  format  for  reporting  diverse  gene
expression array results.
Materials and methods
Experiments and arrays
Array  experiments  used  the  Genetics  Institute  C. elegans
Affymetrix GeneChip oligonucleotide arrays, a set of three
arrays  (denoted  A,  B  and  C)  which  in  aggregate  monitor
approximately 98% of the 19,099 predicted worm mRNAs in
the October 1998 worm genome sequence release [20]. The
total number of probe sets on each array was 6,617 (A array),
5,768 (B), and 6,646 (C). Each probe set consists of 20 dis-
tinct  probe  pairs  (each  probe  is  a  25mer)  designed  to
monitor  a  single  transcript.  On  the  C. elegans arrays
described here, probe sets monitoring the spiked transcripts
were each tiled twice with a different set of oligonucleotide
probes.  On  arrays  that  are  commercially  available  from
Affymetrix,  one  probe  set  is  tiled  to  monitor  each  of  the
spike-in transcripts. The probe sets are not fully randomly
distributed  across  the  arrays,  although  on  the  C. elegans
arrays the different probe sets are tiled in widely different
regions  of  the  arrays.  Experimental  array  data  described
here were taken from the developmental time course dataset
reported in [10]. Specifically, we examined individual repli-
cate hybridizations of the A array from the worm develop-
mental time course at each of 0 (n = 4), 36 (n = 3), 48 (n =4 )
and 60 (n = 4) hours after synchronization of worm eggs by
bleach,  as  well  as  a  larger  set  of  13  hybridizations  of  all
three arrays to samples ranging from oocytes to 2-week-old
worms.  Replicate  hybridizations  in  the  datasets  included
independently  generated  complementary  RNA  (cRNA)
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Table 2
Ratios of across- to within-array coefficients of variation (CVs)
Metric Transcript
K10B3.8 K11C4.5 M03F4.2
AD 2.9 4.2 3.6
ADs 6.4 3.2 6.1
F 2.8 3.0 2.7
Fs 1.3 1.6 1.5
Ratios of across- to within-array CVs. Across-array and within-array CVs
were computed for three worm transcripts. The ratio of across-array to
within-array CV is shown. Across-array CV was computed from
measurements of the same probe set across three different worm array
designs (A, B and C). Within-array CV was computed from serial
measurements of the same probe set within the same array design. Ratios
for the Fs metric are closer to 1 than those for the ADs metric, indicating
that measurements of the same transcript on different array designs were
more reproducible in the Fs metric than the ADs metric. preparations from the same starting total RNA. Primary data
for all transcripts on all arrays (including all replicates of all
three array designs) is contained in the supplementary Excel
spreadsheet (see Additional data files). 
Spike-in transcript pool
A  pool  of  biotin-labeled  spike-in  control  transcripts  was
derived by in vitro transcription of 11 cloned Bacillus subtilis
genes,  using  the  methods  described  in  [21].  The  spike-in
pool was added into hybridization cocktails in proportion to
the UV-quantitated cRNA mass in the hybridization, so as to
achieve  the  desired  final  concentration  of  spike-ins.  The
spiked  transcripts  and  their  final  concentrations  in  the
hybridization cocktails are listed in Table 1. Final concentra-
tions in pmol and parts per million (ppm) for each spiked
transcript  were  computed  from  the  known  length  of  each
spike-in,  assuming  a  total  mass  of  2 g  worm  cRNA  in  a
200 l hybridization volume, and an average length of 1,000
bases for in vitro transcribed worm cRNAs.
Metrics for transcript abundance
Average difference (AD) is the basic measure of transcript
abundance that is calculated by the Affymetrix GeneChip 3.1
software. The calculation of AD is described in detail in the
Affymetrix GeneChip User Guide [17]. Briefly, a background
intensity is computed for each of 16 rectangular sectors on
the  array.  This  local  background  is  subtracted  from  the
intensity values of each probe cell in all sectors. After back-
ground  subtraction,  the  difference  between  perfect  match
(PM) and mismatch (MM) feature intensity is calculated for
all probe pairs in each probe set (in our case, 20 probe pairs
in total). The AD for each probe set is the average of the PM -
MM differences, after outlying values are removed. 
A second important metric generated by the GeneChip soft-
ware is the Absolute Decision. The Absolute Decision is a
categorical call for each transcript: either Present, Absent,
or  Marginal.  The  Absolute  Decision  is  a  heuristic  metric
based on the number of probe pairs for a given transcript
that  show  strong  specific  hybridization  signals.  See  the
Affymetrix GeneChip User Guide [17] for a detailed descrip-
tion of this metric.
Because of array-to-array variation in overall signal strength,
AD values from different arrays are usually normalized to a
common scale. We reproduced the scaled AD normalization of
the  Affymetrix  GeneChip  3.1  software.  The  calculation  is
described  in  detail  in  the  Affymetrix  GeneChip  User  Guide
[17]. Scaling is done by equalizing the average intensity of all
arrays  in  a  given  dataset,  where  the  average  intensity  is
defined  as  the  trimmed  average  of  the  AD  values  of  every
probe set on the array, excluding the highest 2% and lowest
2% of the values. This normalization works on the assumption
that the summed expression level of all genes on the array is
constant across experiments, and that differences in expres-
sion levels between arrays can be corrected by array-specific
scaling  factors.  We  denote  the  normalized  AD  values  as
scaled average difference (ADs).
The calculation of frequency (F) values involved two steps:
first, conversion of AD values to frequencies by use of the
calibration curve, and second, estimation of the chip sensi-
tivity of detection and ‘damping’ of frequency values below
this sensitivity.
The calibration curve for each hybridization was constructed
from the AD values for each of the 11 control transcripts and
their known frequencies (Table 1). AD values that were nega-
tive, or associated with Absent or Marginal Absolute Deci-
sions, were removed from the curve in order to improve the
robustness of the fit. This calibration curve was fitted by a
linear function with zero intercept, using a generalized linear
model  [22]  fitting  procedure  in  the  statistical  software
S-PLUS  (Insightful  Corp.,  Seattle,  WA).  The  fitting  proce-
dure assumed a gamma error structure, appropriate for data
with constant coefficient of variation, and utilized iterative
reweighting of errors. The single coefficient of this linear fit
was multiplied with the average difference values for each
gene on the array to yield initial frequency estimates. Cali-
bration  curves  for  the  hybridizations  described  here  were
examined visually to rule out poor curve fits.
Chip  sensitivity  of  detection  was  estimated  from  the
Absolute Decisions (Present, Marginal, or Absent) for the 11
spike-in transcripts in one of two ways. In the general case,
Absolute  Decisions  were  considered  as  a  binary  response:
Absent  =  0,  Present  =  1,  with  Marginal  calls  treated  as
Absent  to  be  conservative.  This  response  was  regressed
against the log-transformed known frequencies, using a gen-
eralized linear model with a logit link function. The chip sen-
sitivity  was  then  defined  as  the  frequency  at  which  the
predicted odds of a Present call were 70%. In the special case
where all spike-in mRNAs called Absent were lower-abun-
dance messages than all spike-ins called Present, the sensi-
tivity was defined by linear interpolation as the frequency
70%  of  the  distance  between  the  highest  Absent  call  fre-
quency and the lowest Present call frequency.
Frequency values for all genes on the array that fell below
the sensitivity were damped as follows. Negative frequencies
(corresponding to negative AD values) were adjusted to one-
half of the chip sensitivity. Frequencies between zero and the
chip sensitivity were adjusted to the average of the frequency
and the chip sensitivity. The rationale for this adjustment
was threefold. First, one-half the chip sensitivity was a rea-
sonable a priori estimate of abundance for many genes that
were not reliably detected. Second, the adjusted frequencies
were guaranteed to be positive-valued, making downstream
analyses of frequency values (for example, log transforma-
tion) significantly easier. Third, retaining the adjusted low-
level frequency estimates was preferable to discarding them,
because discarding the values would make it impossible to
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http://genomebiology.com/2001/2/12/research/0055.11detect  potentially  important  regulation  of  these  genes  in
future experiments. 
Frequency  normalization  could  be  adversely  affected  by
technical  uncertainties  in  cRNA  preparation  (see  Results
and discussion). To attenuate these effects, an additional fre-
quency variant termed scaled frequency (Fs) was introduced.
Fs was a hybrid of ADs and frequency, and was computed as
follows.  ADs was  first  computed  for  a  set  of  two  or  more
arrays exactly as described above. Then a linear model (with
zero intercept) was fitted to the pooled ADs values for the 11
spike-in transcripts from all arrays, ignoring negative ADs
values  or  those  associated  with  Marginal/Absent  Absolute
Decisions. The slope of this linear model was the single cali-
bration factor for the entire dataset. This slope was multi-
plied with the ADs values from all arrays to yield Fs values.
Per-array  sensitivity  values  were  computed  exactly  as
described for F, and Fs values on any array that were below
the array sensitivity were adjusted as described above.
Simulated data 
Array data was simulated as follows. First, a single experi-
mental dataset, one of the 0-hour replicates, was chosen as a
baseline for generation of all simulated data. To this baseline
dataset, several random noise sources were added to repro-
duce  key  sources  of  variability  in  array  data.  The  relation
describing the simulated data was:
ADij = bij + ADBi (aj mij sij rij)
where 
ADij = simulated AD for the ith mRNA on the jth array
ADBi = baseline gene expression data for the ith mRNA
bij = background noise for the ith mRNA on the jth array
aj = array intensity offset for the jth array
mij = multiplicative noise for the ith mRNA on the jth array 
sij = spike-skew factor for the ith mRNA on the jth array
(unity for all nonspiked mRNAs)
rij = regulation factor for the ith gene on the jth array (unity
for all spiked mRNAs)
Background bij was Gaussian with a standard deviation (SD)
that varied randomly from one array to another. The back-
ground noise SD had a mean of 20 AD units, and a standard
deviation  of  5  AD  units.  Array  intensity  offsets  aj were
Gaussian with a mean of one and SD of 0.3. Multiplicative
noise, mij, was drawn from a normally distributed zero-mean
noise source with a constant CV of 0.1. Spike-skew factor sij
was a single random factor for all spiked cRNAs on a given
array,  and  unity  for  all  other  messages.  The  spike-skew
factor for the spiked cRNAs was Gaussian with mean 1 and a
SD that was adjusted from 0.1 to 0.4 (in percentage terms,
10-40%). Regulation factors rij were generated by a proce-
dure in which the base-10 log (fold-change) for each gene
was selected from a normal distribution with mean 0 and SD
0.5. Extreme random regulation factors were limited so that
the regulated gene expression values had the same range as
baseline data. After multiplication of each gene by its regula-
tion  factor,  the  mean  expression  level  of  all  genes  was
adjusted  so  that  the  overall  mean  expression  level  was
unchanged by regulation.
Additional data files
Primary  data  for  all  experimental  hybridizations  are  pro-
vided with the online version of this article.
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